Open AccessS0800 Safety and Efficacy of Vedolizumab vs Tumor Necrosis Factor Antagonists in an Elderly IBD Population
Author(s) -
C. Alex Wiles,
Baldeep Pabla,
Chris Slaughter,
Elizabeth Scoville,
Robin Dalal,
Dawn Beaulieu,
David A. Schwartz,
Sara N. Horst
Publication year - 2020
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000705248.77205.de
Subject(s) - medicine , vedolizumab , cohort , population , discontinuation , interquartile range , retrospective cohort study , infliximab , inflammatory bowel disease , surgery , tumor necrosis factor alpha , disease , environmental health
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom